Neuland Laboratories has announced a significant milestone in its growth strategy. The company has successfully commenced commercial production following the expansion of its Unit 3 manufacturing facility located in Telangana.

Expansion Details

The expanded facility is situated at Survey No. 10, Plot No. 3-72, Gaddapotharam Village, Jinnaram Mandal, Sangareddy District, Telangana - 502 319. This strategic expansion is expected to boost Neuland's production capabilities and strengthen its position in the pharmaceutical manufacturing sector.

Timeline of Expansion

The company had previously informed stakeholders about its expansion plans through a letter dated November 10, 2023. The recent announcement marks the successful implementation of these plans, with the additional capacity now operational.

Regulatory Compliance

In compliance with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015, Neuland Laboratories has duly informed the stock exchanges about this development. The company's commitment to transparency is evident in its prompt disclosure of this material information to its shareholders and the market at large.

Impact on Operations

The commencement of commercial production at the expanded Unit 3 facility is a significant step for Neuland Laboratories. This expansion is likely to enhance the company's manufacturing capabilities, potentially leading to increased production volumes and improved operational efficiency.

Market Implications

While the specific details of the capacity increase have not been disclosed, the expansion is expected to positively impact Neuland's ability to meet market demand. This development may be of particular interest to investors and industry analysts monitoring the company's growth trajectory and market position in the pharmaceutical sector.

Neuland Laboratories continues to demonstrate its commitment to growth and operational excellence through strategic expansions such as this. As the company leverages its enhanced production capabilities, stakeholders will be keen to observe the impact on its financial performance and market standing in the coming quarters.

Neuland Laboratories has initiated a postal ballot process to seek shareholder approval for the appointment of Dr. Ravi Shankar Gopinath as an Independent Director. The company's Board of Directors, based on recommendations from the Nomination and Remuneration Committee, has proposed Dr. Gopinath's appointment for a five-year term.

Key Details of the Appointment

• Proposed Term: August 1, 2025, to July 31, 2030
• Position: Independent Director, not liable to retire by rotation
• Approval Process: Special Resolution through remote e-voting

About Dr. Ravi Shankar Gopinath

Dr. Gopinath, 59, brings a wealth of experience to Neuland Laboratories:

• Educational Background: Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute, New York; Masters in Chemical Engineering from IIT, Bombay
• Professional Experience:
  • Started career as a research scientist at Tata Consultancy Services (TCS)
  • Served as MD and CEO of Geometric Ltd.
  • Held leadership roles at AVEVA plc, including COO, CPO, and CSO
  • Executive positions at Schneider Electric Software and Invensys Software

Expertise and Competencies

Dr. Gopinath's areas of expertise include:

• Strategy formulation and execution
• Application of digital technologies
• Driving operational excellence
• M&A transactions and integration
• Organization change and leadership development

E-Voting Details

Board's Recommendation

The Board of Directors recommends the appointment of Dr. Ravi Shankar Gopinath, citing his rich experience and vast knowledge as a business leader. They believe his expertise aligns well with the company's needs and would be of immense benefit to Neuland Laboratories.

Shareholders are encouraged to participate in the e-voting process to cast their votes on this important appointment. The results of the postal ballot will be announced on or before September 28, 2025, at the company's registered office and will be communicated to the stock exchanges where Neuland Laboratories' securities are listed.